Acino to acquire Cephalon's Middle East and African business

NEWS RELEASE — PRESSEMITTEILUNG
Acino to acquire Cephalon’s Middle East and African
business
Basle, October 14, 2011, 12.30 hrs — Acino and Cephalon Inc. have today entered
into an agreement under which Acino will acquire Cephalon’s combined Middle East
and African business for a total consideration of approximately EUR 80 million. Under
the terms of the agreement, Acino will pay EUR 60 million in cash and EUR 20 million
through the issuance of shares from authorized capital (calculated at the average share
price on the day prior to the closing of the transaction). Acino expects the acquisition to
be immediately accretive.
The business to be acquired, which includes Cephalon and Mepha brands, is expected
to generate sales of close to EUR 100 million in 2011. The well established product
portfolio comprises leading brands including the analgesic Olfen (diclofenac), the antispasmotic
Spasfon (phloroglucinol/trimethylphloroglucinol), the gastrointestinal drug
Gasec (omeprazole) and the antibiotic Mesporin (ceftriaxone).
Through this transaction, Acino makes a quantum leap towards establishing its own
market presence in emerging markets. Peter Burema, Acino’s CEO, stated; “This is a
game-changing acquisition for our company and underpins our commitment to building
Acino’s own market presence in up-and-coming economies. The acquired products
ideally complement our own portfolio. The Mepha legacy, built on its Swiss heritage, will
live on through this acquisition by Acino, also headquartered in Switzerland and committed
to the same high quality standards”.
Over the last 18 months, Acino’s Management has refined its growth strategy to focus
on three complementary business pillars: selling the products it develops through its
partners in the developed markets, establishing its own market presence under its
“Acino Switzerland” brand in emerging markets, and entering into development programs
with innovative pharmaceutical companies based on its expertise in drug delivery
technology.
About Cephalon / Mepha
Cephalon is an international biopharmaceutical company dedicated to discovering, developing
and bringing to market medications for difficult to treat and rare conditions. Since its inception in
1987, Cephalon has brought first-in-class and best-in-class medicines to patients around the
world in several therapeutic areas. Swiss-based pharmaceutical company Mepha, a subsidiary of
Cephalon, develops and manufactures its products in Aesch/Basel (Switzerland) with a strong
Acino Holding Ltd.
Erlenstrasse 1
CH-4058 Basle
Phone +41 61 338 60 00
Fax +41 61 338 60 80
www.acino-pharma.com

focus on Swiss-quality standards. Through partnerships, Mepha markets its products in other
European countries, in the Middle East, Africa, South and Central America as well as in Asia.
For more information visit www.cephalon.com or www.mepha.com .
Acino – Delivering Health
Acino Pharma Ltd. (SIX: ACIN), a Swiss-based pharmaceutical company, develops and manufactures
generic and innovative pharmaceuticals using advanced drug delivery technologies, for
which it also holds patents. With a focus on sophisticated oral dosage forms with modified release
of the active ingredient, transdermal therapeutic patches and biodegradable, subcutaneous implants,
Acino supplies leading pharmaceutical companies worldwide. Acino offers the pharmaceutical
industry a comprehensive range of services from product development and registration to
sourcing, contract manufacturing, packaging and logistics. The Acino Group is headquartered in
Basle (Switzerland), currently employs 443 staff and generated annual revenues of EUR 128 million
in 2010.
Contact Calendar
Peter Burema
CEO Acino Group
Phone +41 61 338 60 00
info@acino-pharma.com
www.acino-pharma.com
Page 2 / 2
9.3.12 Annual Report 2011
9.3.12 Media & analyst conference
5.4.12 Annual General Meeting
Acino Holding Ltd.
Erlenstrasse 1
CH-4058 Basle
Phone +41 61 338 60 00
Fax +41 61 338 60 80
www.acino-pharma.com